L’exploitation d’un modèle de levure présentant une déficience de l’absorption des anthracyclines révèle qu’une protéine de Caenorhabditis elegans, OCT-1, est un transporteur fonctionnel d’anthracyclines
Anthracyclines such as doxorubicin (DOX) or daunorubicin (DNR) are used for treatment of a wide variety of cancers from lymphomas to breast cancer going through some leukemia. Still today, several people think that anthracyclines enter cells through passive diffusion, but these same people believe that the p-glycoprotein is involved in efflux of anthracyclines. We think that there is a transporter responsible for uptake of anthracyclines by cells and we want to develop a yeast model that would allow us to determine if protein from another eukaryote organism could be able to transport DOX into yeast cells. In order to do that, we gathered a group of mutants that are already known to be resistant to other positively charged molecules such as bleomycin and NaD1 and determined their ability to take up DOX. The simple mutants sam3Δ or dur3Δ showed no or slight decrease of DOX compared to parent. If the double mutant sam3Δdur3Δ showed rather significant uptake decrease, it is the agp2Δ that showed the grater decrease in DOX uptake as a resistance to its lethal effect. We used that mutant to express a protein from the worm Caenorhabditis elegans, OCT-1 (CeOCT-1). The results showed that this protein was able restore back the uptake of DOX that was compromised in agp2Δ and was also able to increase the sensitivity of the parent to its lethal effect. This leads us to believe that CeOCT-1 is functional transporter for DOX and goes against the dogma wherein anthracyclines enter the cells through passive diffusion.
Caenorhabditis elegans OCT-1 Uptake Yeast Transporters